Showing results (1-10 of 218) with videos related to
Sort By:
Pageof 22
Cancers|February 13, 2025
Improving Treatment Options for Patients with Double Refractory CLLRyan Jacobs, William WierdaJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Investigational immunotherapeutics for B-cell malignanciesAlfonso Quintás-Cardama, William Wierda, Susan O'BrienCurrent Hematologic Malignancy Reports|April 29, 2010
New aspects of the treatment of chronic lymphocytic leukemiaStefan Faderl, William Wierda, Michael J KeatingJournal of Blood Medicine|January 28, 2012
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)Aref Al-Kali, William Wierda, Michael Keating, et al.Frontiers in Oncology|June 21, 2024
The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapyRyan Jacobs, Caron JacobsonLeukemia Research|November 26, 2015
Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLLJoshua Kellner, William Wierda, Elizabeth Shpall, et al.Current Hematologic Malignancy Reports|October 20, 2018
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin LymphomaBei Hu, Ryan Jacobs, Nilanjan GhoshData in Brief|June 13, 2018
Data and Supplemental information for predicting the thermodynamic stability of perovskite oxides using machine learning modelsWei Li, Ryan Jacobs, Dane MorganClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonucleaseAlma Zecevic, Deepa Sampath, Brett Ewald, et al.Cancer|March 13, 2010
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrenceStefan Faderl, Alessandra Ferrajoli, William Wierda, et al.Pageof 22